Study	Intervention name	Results		Unit of analysis	Time point	Type of assay	Population
		GMT (95% CI)	GMR (95% CI)
COVID‐19 vaccine versus placebo
Frenck 2021	BNT162b2	1283.00 (1139.60 to 1444.50)	84.96 (58.90 to 122.55)	Not specified	1 month after 2nd dose	SARS‐CoV‐2 50% neutralizing assay	12–15 years
	Placebo	15.10 (10.70 to 21.40)
	BNT162b2	730.80 (646.70 to 825.80)	68.29 (56.55 to 82.48)	Not specified	1 month after 2nd dose	SARS‐CoV‐2 50% neutralizing assay	16–25 years
	Placebo	10.70 (9.30 to 12.40)
Walsh 2020	BNT162b2	163 (no CIs)	16.30	Not specified	14 days after 2nd dose (time point not specified for placebo)	SARS‐CoV‐2 serum 50% neutralizing assay	18–55 years
	Placebo
	BNT162b2	206 (no CIs)	20.60	Not specified	14 days after 2nd dose (time point not specified for placebo)	SARS‐CoV‐2 serum 50% neutralizing assay	65–85 years
	Placebo